Uncategorised - European Medical Journal

Continue
1 Mins
12th November 2019

Intervention in Malaria Parasite Journey May Reduce Disease Transmission

THE JOURNEY taken by malaria Plasmodium parasites for invasion of the liver may now be detectable, according to a new study…
1 Mins
12th November 2019

Delayed Onset of Alzheimer’s Initiated by Anticoagulant in Mice

DELAYED onset of Alzheimer’s disease caused by a well-known anticoagulant has been demonstrated in a mouse model…
1 Mins
12th November 2019

Predicting Methotrexate Response in Rheumatoid Arthritis Patients

CHANGES in DNA methylation at 4 weeks of methotrexate treatment for rheumatoid arthritis (RA) were associated with improvements in symptoms at 6 months…
1 Mins
12th November 2019

Shedding New Light on Chronic Pain Link to Weather

“AROUND three-quarters of people living with arthritis believe their pain is affected by the weather,” explains Prof Will Dixon…
12 Mins
12th November 2019

Review of the European Society for Medical Oncology (ESMO) Congress 2019

Barcelona, a city with undisputed character, ambience, and beauty, played host this year to the prestigious annual European Society…
1 Mins
12th November 2019

A Novel Affinity-Enhanced NY-ESO-1-Targeting TCR-Redirected T cell Transfer Exhibiting Early-Onset Cytokine Release Syndrome and Subsequent Tumour Responses in Synovial Sarcoma Patients

Adoptive transfer of T cell receptor (TCR)-redirected T cells has been reported to exhibit efficacy in some patients with melanoma and sarcoma…
9 Mins
12th November 2019

Inflection Point: Novel Treatment Options are Forcing Next-Generation Sequencing into Standard of Care for Molecular Profiling in Oncology

With a sustained number of new drugs or combination drugs entering standard of care this year, molecular testing should be…
9 Mins
12th November 2019

The Anticancer Power of the Immune System – New Perspectives for Patients with Triple-Negative Breast Cancer

Despite the impressive advances that have been made in cancer diagnosis and therapy, there still exist groups of patients who are not responding to standard anticancer treatments…
2 Mins
12th November 2019

A Phase II Study of Pazopanib as Front-Line Therapy in Patients with Nonresectable or Metastatic Soft Tissue Sarcomas Who are Not Candidates for Chemotherapy

Patients with metastatic soft tissue sarcoma (STS) have a poor prognosis with a median survival of 12–14 months.1 First-line therapy consists…
3 Mins
12th November 2019

Balancing the Scales: The Fight for Female Representation in Oncology

As exciting and momentous as the progression in medical oncology continues to be, a different type of progression is still sorely needed across…